Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer

Journal of International Medical Research

Volumn 42, Issue 3, 2014, Pages 737-743

  Dong, Lei ^a   Li, Jing ^a   Lou, Xiao Ping ^a   Miao, Jin Hong ^a   Lu, Pei ^a   Chang, Zhi Wei ^a   Han, Zhao Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Advanced gastric cancer; DCF regimen; S 1; TIROX regimen

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NEUROTOXICITY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STOMACH CANCER; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; LYMPH NODE METASTASIS; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; LEUKOPENIA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PROSPECTIVE STUDIES; RECURRENCE; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 84904749569     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513510657     Document Type: Article

References (29)

1. Crew KD,Neugut AI.Epidemiology of gastric cancer.World J Gastroenterol. 2006;12:354-362.
2. Parkin DM,Bray F,Ferlay J, et al.Estimating the world cancer burden: Globocan 2000.Int J Cancer. 2001;94:153-156.
3. Dicken BJ,Bigam DL,Cass C, et al.Gastric adenocarcinoma: review and considerations for future directions.Ann Surg. 2005;241:27-39.
4. Brenner H,Rothenbacher D,Arndt V.Epidemiology of stomach cancer.Methods Mol Biol. 2009;472:467-477.
5. Takahashi T,Saikawa Y,Kitagawa Y.Gastric cancer: current status of diagnosis and treatment.Cancers (Basel). 2013;5:48-63.
6. Wang S-B,Wang J.Problems about recurrent or metastatic gastric cancer and its integrative treatment.Chinese Journal of Bases and Clinics in General Surgery. 2006;1:1-7.
7. Mackenzie M,Spithoff K,Jonker D.Systemic therapy for advanced gastric cancer: a clinical practice guideline.Curr Oncol. 2011;18:e202-e209.
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer, http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (2014, accessed 8 February 2014).
9. Oken MM,Creech RH,Tormey DC,Horton J,Davis TE,McFadden ET,Carbone PP.Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649-655.
10. Park SR,Kong SY,Rhee J, et al.Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.Ann Oncol. 2011;22:890-896.
11. Therasse P,Arbuck SG,Eisenhauer EA, et al.New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst. 2000;92:205-216.
12. Trotti A,Byhardt R,Stetz J, et al.Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.Int J Radiat Oncol Biol Phys. 2000;47:13-47.
13. Hsiao CF,Xu JZ,Liu JP.A two-stage design for bridging studies.J Biopharm Stat. 2005;15:75-83.
14. Wang Y,Liu L,Liu X, et al.Shugoshin1 enhances multidrug resistance of gastric cancer cells by regulating MRP1, Bcl-2, and Bax genes.Tumour Biol. 2013;34:2205-2214.
15. Kimura Y,Yano H,Imamura H, et al.A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.Jpn J Clin Oncol. 2013;43:125-131.
16. Hoff PM,Wenske C,Medgyesy D, et al.Phase I and pharmacokinetic study of the novel oral fluoropyrimidine, S-1.Proc Am Soc Clin Oncol. 1999;18:173-173.
17. Kobayakawa M,Kojima Y.Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.Onco Targets Ther. 2011;4:193-201.
18. Koizumi W,Kurihara M,Nakano S, et al.Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.Oncology. 2000;58:191-197.
19. Blum M,Suzuki A,Ajani JA.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinomas.Future Oncol. 2011;7:715-726.
20. Ajani JA,Rodriguez W,Bodoky G, et al.Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.J Clin Oncol. 2010;28:1547-1553.
21. Rixe O,Ortuzar W,Alvarez M, et al.Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.Biochem Pharmacol. 1996;52:1855-1865.
22. Kristensen MH,Pedersen P,Mejer J.The value of dihydrourail/uracil plasma ratios in predicting 5-flurouracil-related toxicity in colorectal cancer patients.J Int Med Res. 2010;38:1313-1323.
23. Montagnani F,Turrisi G,Marinozzi C, et al.Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis.Gastric Cancer. 2011;14:50-55.
24. Ando Y,Saka H,Ando M, et al.Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.Cancer Res. 2000;60:6921-6926.
25. Morishita Y,Fujii M,Kasakura Y, et al.Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan.J Int Med Res. 2005;33:84-89.
26. Chen AY,Chen PM,Chen YJ.DNA topoisomerase I drugs and radiotherapy for lung cancer.J Thorac Dis. 2012;4:390-397.
27. Kusaba H,Esaki T,Futami K, et al.Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.Cancer Sci. 2010;101:2591-2595.
28. Altinbas M,Er O,Ozkan M, et al.Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.Med Oncol. 2005;22:153-160.
29. Cao W,Yang W,Lou G, et al.Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.Anticancer Drugs. 2009;20:287-293.